In This Article:
Contineum Therapeutics has concluded the targeted enrolment of 168 subjects in its Phase II trial of M1 receptor antagonist PIPE-307 to treat relapsing-remitting multiple sclerosis (RRMS).
Named PIPE-307 VISTA, the randomised, double-blind, placebo-controlled, multicentre, proof-of-concept trial is evaluating the efficacy and safety of PIPE-307 in RRMS patients.
Participants will be randomised in a 1:1:1 ratio into one of three cohorts to receive two different doses of PIPE-307 or a placebo.
The study will last approximately 30 weeks and is designed to assess multiple clinical and imaging endpoints that are sensitive to changes in remyelination in RRMS patients.
The company expects the last patient to complete the trial by the third quarter of this year.
Contineum Therapeutics chief medical officer Stephen Huhn said: “We are pleased to reach this significant milestone for the PIPE-307 VISTA trial ahead of schedule.
“The trial is designed to show evidence of remyelination as a potentially first-in-class and differentiated therapy for RRMS patients. We believe that PIPE-307 could represent the next evolution in the treatment paradigm for RRMS. We are grateful for the VISTA trial investigators, patients, and their families, and we look forward to sharing topline data from this trial.”
Contineum is developing PIPE-307 under a global licence and development agreement with Janssen Pharmaceutica NV, a Johnson & Johnson company.
Apart from PIPE-307, the company is also developing a lysophosphatidic acid 1 receptor antagonist, PIPE-791, for treating idiopathic pulmonary fibrosis, progressive multiple sclerosis, and chronic pain.
In December 2024, the company dosed the first subject cohort in the Phase Ib positron emission tomography (PET) trial of brain-penetrant small molecule PIPE-791.
"Contineum concludes enrolment in Phase II multiple sclerosis therapy trial" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.